The growing clinical success of hematopoietic stem/progenitor cell (HSPC) gene therapy
(GT) relies on the development of viral vectors as portable" Trojan horses" for safe and …

Nanomaterials have the potential to improve how patients are clinically treated and
diagnosed. While there are a number of nanomaterials that can be used toward improved …

Clinical application of umbilical cord blood (UCB) as a source of hematopoietic stem cells for
transplantation is limited by low CD34+ cell dose, increased risk of graft failure, and slow …

It has been recently shown that increased oxidative phosphorylation, as reflected by
increased mitochondrial activity, together with impairment of the mitochondrial stress …

Omidubicel is an ex vivo expanded hematopoietic progenitor cell and nonexpanded myeloid
and lymphoid cell product derived from a single umbilical cord blood unit. We report results …

Purpose Increasing the number of hematopoietic stem and progenitor cells within an
umbilical cord blood (UCB) graft shortens the time to hematopoietic recovery after UCB …

Umbilical cord blood transplantation (UCBT) has been performed in the clinic for over 30
years. The biological and immunological characteristics of umbilical cord blood (UCB) have …

Genetic engineering of hematopoiesis: current stage of clinical translation and future
perspectives | EMBO Molecular Medicine Skip to Article Content Skip to Article Information All …

The first hematopoietic transplant in which umbilical cord blood (UCB) was used as the
source of hematopoietic cells was performed in October 1988. Since then, significant …

Hematopoietic stem cells (HSCs) are fundamental to the generation of the body's blood and
immune cells. They reside primarily within the bone marrow (BM) niche microenvironment …